ABSTRACT
Myoblast
implantation is a unique, patented technology of muscle regeneration being
tested in Phase III clinical trials of muscular dystrophy, ischemic
cardiomyopathy, Phase II trial of cancer, and Phase I trial of Type II diabetes.
Differentiated and committed, myoblasts are not stem cells. Implanted myoblasts fuse spontaneously among
themselves, replenishing genetically normal myofibers. They also fuse with genetically abnormal myofibers of
muscular dystrophy, cardiomyopathy, or Type II diabetes, transferring
their nuclei containing the normal human genome to provide stable, long-term
expression of the missing gene products. They develop to become cardiomyocytes
in the infracted myocardium. Myoblasts transduced with VEGF165 allow
concomitant regeneration of blood capillaries and myofibers. They are potent
biologics for treating heart failure, ischemic cardiomyopathy, diabetic
ischemia, erectile dysfunction, and baldness. Myoblasts, because of their small
size, spindle shape, and resilience, can grow within wrinkles and on skin surfaces,
thus enhancing the color, luster and texture of the skin “plated” with them.
They can be injected subcutaneously as a cellular filler to reduce wrinkles.
Intramuscular injection of myoblasts can augment the size, shape, consistency,
tone and strength of muscle groups, improving the lines, contours and vitality to
sculpt a youthful appearance. This highly promising technology has great social
economic values in treating hereditary, fatal and debilitating disease
conditions.